What medications can cause direct tubular injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medications That Cause Direct Tubular Injury

Several classes of medications can cause direct tubular injury, with aminoglycosides, platinum-based chemotherapy agents, and certain other nephrotoxic drugs being the most common culprits. 1

Aminoglycoside Antibiotics

Aminoglycosides are among the most well-documented causes of direct tubular injury:

  • Gentamicin: Causes acute tubular necrosis through direct toxicity to proximal tubular cells 2
  • Tobramycin: Primarily manifests as acute tubular necrosis with signs including rising BUN and creatinine, decreased urinary output, and urinary losses of sodium, potassium, bicarbonate, magnesium, phosphate, and calcium 3

The nephrotoxicity risk with aminoglycosides increases with:

  • Drug accumulation (trough levels above 2 mcg/mL)
  • Excessive peak concentrations (above 12 mcg/mL)
  • Total cumulative dose
  • Advanced age
  • Volume depletion
  • Concurrent use of other nephrotoxic drugs
  • Diabetes 3

Chemotherapeutic Agents

Several anticancer drugs cause direct tubular injury:

  • Cisplatin: Causes cross-linking and interference with DNA replication, leading to acute tubular injury and necrosis, proximal tubulopathy, Fanconi syndrome, and electrolyte wasting 1
  • Ifosfamide: Nitrogen mustard alkylating agent that causes acute tubular injury and necrosis 1
  • Pemetrexed: Antifolate agent that causes acute tubular injury and necrosis 1
  • Methotrexate: Causes both crystalline nephropathy and acute tubular injury 1

Bisphosphonates

  • Pamidronate: Associated with moderate FPPS inhibition, causing focal segmental glomerulosclerosis and acute tubular injury 1
  • Zoledronic acid: More potent FPPS inhibitor that causes acute tubular injury and necrosis 1

Targeted Therapies

  • BRAF inhibitors (vemurafenib and dabrafenib): Cause acute tubular injury through inhibition of mutated BRAF V600E kinase 1
  • ALK inhibitors (crizotinib): Cause acute tubular injury through inhibition of mutated anaplastic lymphoma kinase 1

Other Medications

  • Radiocontrast agents: Cause direct kidney tubule toxicity 1
  • Amphotericin B: Direct tubular toxin 1
  • Vancomycin: Can cause acute tubular injury, particularly at high doses 4

Mechanisms of Tubular Injury

Medications can cause direct tubular injury through several mechanisms:

  1. Direct cellular toxicity: Drugs like aminoglycosides and cisplatin directly damage tubular cell mitochondria and other cellular components 4

  2. Transport-mediated injury: Some drugs accumulate in tubular cells through specific transporters:

    • Aminoglycosides enter via endocytosis at the apical membrane
    • Cisplatin enters via organic cation transporters at the basolateral membrane
    • Tenofovir enters via organic anion transporters 4
  3. Intratubular crystal formation: Drugs like methotrexate can precipitate within tubular lumens 4

Prevention Strategies

To minimize the risk of medication-induced tubular injury:

  • Use the shortest duration of therapy clinically appropriate
  • Ensure adequate hydration during treatment
  • Limit concurrent use of other nephrotoxic drugs
  • Monitor drug levels closely (especially for aminoglycosides)
  • Consider alternative less nephrotoxic medications when possible 5
  • Monitor renal function, electrolytes, urine output, and urinalysis during therapy 3

Clinical Monitoring

For high-risk medications like aminoglycosides:

  • Monitor serum drug concentrations to avoid toxic levels
  • Check renal function before and during treatment
  • Adjust dosing based on renal function
  • Consider once-daily dosing regimens when appropriate 5

For patients receiving potentially nephrotoxic medications, early detection of tubular injury is crucial for preventing progression to more severe kidney damage and improving outcomes.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Nephrotoxicity Associated with Aminoglycosides

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.